Skip to content

Gene Polymorphism in Tinea Versicolor

Detection of IL1-7A and IL-17F Gene Polymorphism in Pityriasis Versicolor and Its Relation to Susceptibility to Infections.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04769804
Enrollment
200
Registered
2021-02-25
Start date
2019-11-01
Completion date
2021-11-01
Last updated
2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Pityriasis Versicolor

Brief summary

Blood samples will be taken from cases presenting with recurrent tinea versicolor , after confirmation of diagnosis by wood's light and KOH examination, for the detection of gene polymorphism in IL17 A and IL17 F. In addition , serum samples from patients and controls will be tested for 25(OH)2 D3

Interventions

None listed

Sponsors

Kasr El Aini Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years

Inclusion criteria

* \- Patients with recurrent pityriasis versicolor (active now) and not taking treatment for it. * Patients of both genders. * Age ≥18 years old.

Exclusion criteria

* \- Patients with other cutaneous diseases. * Patient's having dandruff (scaly scalp) even if not symptomatizing. * Pregnant and lactating females, children, prisoners, cognitively impaired or mentally disabled subjects. * Patients with autoimmune diseases. * Patients with immunodeficiency diseases. * Immunosuppressed patients e.g. HIV, diabetics, organ transplant, malignancy, patients taking immunosuppressive drugs e.g. chemotherapy, cortisone.

Design outcomes

Primary

MeasureTime frameDescription
IL 17A gene polymorphism6months-1 yearIL 17A
IL 17 F gene polymorphism6months-1 yearIL 17 F

Secondary

MeasureTime frameDescription
Vitamin D6months-1 yearSerum 25(OH)2 D3

Countries

Egypt

Contacts

Primary ContactRana Hilal, MD
rana.hilal@kasralainy.edu.eg01001488869

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026